e-learning
resources
Madrid 2019
Tuesday, 01.10.2019
Multidrug resistance in nosocomial pneumonia: burden, magnitude and solution
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
International guidelines for nosocomial pneumonia: do they cover multidrug resistance management?
V. Del Bono (Genoa, Italy)
Source:
International Congress 2019 – Multidrug resistance in nosocomial pneumonia: burden, magnitude and solution
Session:
Multidrug resistance in nosocomial pneumonia: burden, magnitude and solution
Session type:
Hot topic
Number:
3529
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
V. Del Bono (Genoa, Italy). International guidelines for nosocomial pneumonia: do they cover multidrug resistance management?. International Congress 2019 – Multidrug resistance in nosocomial pneumonia: burden, magnitude and solution
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
Antibiotic resistance and clinical outcomes: the CAPNETZ experience
Source: Annual Congress 2006 - PG1 - Respiratory infections: pneumonia/antibiotic resistance and clinical outcome of lower respiratory tract infections
Year: 2006
From international guidelines to local guidelines for nosocomial pneumonia: what is missing?
Source: International Congress 2019 – Multidrug resistance in nosocomial pneumonia: burden, magnitude and solution
Year: 2019
International Guideline concordance of empiric antibiotic use in community-acquired pneumonia
Source: Virtual Congress 2020 – Antibiotic therapy for pneumonia and pleural infections
Year: 2020
Verifying the antibiotic selection algorithm in the new Japanese pneumonia guidelines - Is algorithm-discordant treatment associated with increased mortality of healthcare-associated pneumonia?
Source: International Congress 2018 – Pneumonia: from the community to the intensive care unit
Year: 2018
Management of community-acquired pneumonia: new evidence-based algorithms.
Source: Virtual Congress 2021 – Emerging data for the management of respiratory tract infections
Year: 2021
Hospital-acquired pneumonia: microbiological data and potential adequacy of antimicrobial regimens
Source: Eur Respir J 2002; 20: 432-439
Year: 2002
Antibiotic therapy of community-acquired pneumonia in the hospital setting: national guidelines and real clinical practice.
Source: International Congress 2017 – COPD management
Year: 2017
Dynamic of adherence to guidelines for antibiotic therapy of community-aquired pneumonia (CAP)
Source: Annual Congress 2013 –Antibiotics, resistance and vaccines
Year: 2013
Hospital-acquired pneumonia: coverage and treatment adequacy of current guidelines
Source: Eur Respir J 2003 Dec 01;22(6):876-882
Year: 2003
Guideline-concordant therapy and outcomes in healthcare-associated pneumonia
Source: Eur Respir J 2011; 38: 878-887
Year: 2011
CAP and HAP guidelines: treatment indications and more
Source: Annual Congress 2006 - PG1 - Respiratory infections: pneumonia/antibiotic resistance and clinical outcome of lower respiratory tract infections
Year: 2006
Community acquired pneumonia guidelines: not only treatment indications
Source: Annual Congress 2004 - PG22 - New perspectives in pneumonia treatment and prophylaxis
Year: 2004
Epidemiology, antimicrobial resistance and clinical outcomes in nursing home associated pneumonia compared to community acquired pneumonia
Source: Annual Congress 2013 –Antibiotics, resistance and vaccines
Year: 2013
Summary of the international clinical guidelines for the management of hospital-acquired and ventilator-acquired pneumonia
Source: ERJ Open Res, 4 (2) 00028-2018; 10.1183/23120541.00028-2018
Year: 2018
Summary of the international clinical guidelines for the management of hospital-acquired and ventilator-acquired pneumonia
Source: Guideline 2018
Year: 2019
VAP: approach to therapy
Source: Eur Respir Mon 2011; 53: 36-47
Year: 2011
International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia
Source: Eur Respir J, 50 (3) 1700582; 10.1183/13993003.00582-2017
Year: 2017
International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia
Source: Guideline 2017
Year: 2017
Adherence to guidelines' empirical antibiotic recommendations and community-acquired pneumonia outcome
Source: Eur Respir J 2008; 32: 892-901
Year: 2008
Could the initial use of antipseudomonal agents improve the prognosis for non-hospital acquired pneumonia?
Source: Annual Congress 2013 –Pneumonia and sepsis
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept